Loading, Please Wait...

CST: 20/11/2019 06:00:43   

HTG Introduces the HTG EdgeSeq Mouse mRNA Tumor Response Panel

237 Days ago

TUCSON, Ariz., March 27, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has released a new HTG EdgeSeq Mouse mRNA Tumor Response Panel available now in the United States and Europe. The HTG EdgeSeq Mouse mRNA Tumor Response Panel is designed for use in mouse oncology models to identify and quantify expression of genes and gene pathways from a variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) tissue. The HTG EdgeSeq Mouse mRNA Tumor Response Panel is designed to measure over 1,600 mouse mRNA targets in one RNA extraction-free assay.

“We are pleased with the rate of adoption of our portfolio of HTG EdgeSeq human gene expression assays in biomarker development projects,” stated John Lubniewski, HTG’s President and Chief Operating Officer. “The expansion of our assay portfolio to mouse oncology models meets a customer need for profiling earlier in the biomarker discovery process where a high volume of testing is done. Ultimately, we believe the addition of mouse profiling will enable customers to carry forward from discovery to the patient without changing platforms,” Mr. Lubniewski concluded.

About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.

Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits or outcomes of the release of the HTG EdgeSeq Mouse mRNA Tumor Response Panel. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the HTG EdgeSeq Mouse mRNA Tumor Response Panel may not perform as expected, the risk that the HTG EdgeSeq Mouse mRNA Tumor Response Panel may not be adopted by our customers at the rate that we expect, or at all, risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made .

Contact:
Ashley Robinson
Life Science Advisors, LLC
Phone: (617) 525-7754
Email: arr@lifesciadvisors.com

Is your business listed correctly on America’s largest city directory network of 1,000 portals?